Tenderwize
Back to tender search

Abschluss nicht exklusiver Rabattverträge gemäß §§ 130a Abs. 8/130c Abs. 1 SGB V zu Arzneimitteln mit dem Wirkstoff Ritonavir (J05AE03) im Rahmen eines sogenannten Open-House-Modells.

AOK Rheinland-Pfalz/Saarland - Die Gesundheitskasse·Eisenberg, Germany·Deadline Dec 31, 2026 · 177 days left·Open·Supplies
Structured notice only
Original notice title

Germany – Pharmaceutical products – Abschluss nicht exklusiver Rabattverträge gemäß §§ 130a Abs. 8/130c Abs. 1 SGB V zu Arzneimitteln mit dem Wirkstoff Ritonavir (J05AE03) im Rahmen eines sogenannten Open-House-Modells.

60/100

Opportunity Score

PromisingLow complexity
SuppliesOpen
Why this score?

Opportunity

60 / 100

Complexity

20 / 100

Risk factors

Open-House contracts can be terminated automatically if exclusive contracts are signed during the term, reducing value...

Stringent proof of drug authorization required; delays or missing documents may prevent participation.

Deep Portfolio Analysis

Deep Company Fit Analysis

Uses:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Overview

Strong opportunity

Key Facts

  • Supplies contract
  • 1 lot
  • Duration until Feb 2027
  • Conclusion of non-exclusive discount agreements for Ritonavir (J05AE03) under an Open-House model.
  • Contracts have uniform terms for all participants; no individual negotiations.
Show full summary

This is a non-exclusive discount agreement (Open-House model) for Ritonavir (J05AE03) pharmaceutical products, offered by AOK Rheinland-Pfalz/Saarland. The tender is not a formal public procurement under EU directives but published for transparency. All interested pharmaceutical companies can join on equal terms; contracts are non-exclusive and can be terminated early if exclusive contracts are awarded. The first deadline for initial contracts is 31.01.2025, but applications can be made monthly until 31.12.2026. No estimated value or award criteria are provided. Submission is non-electronic, in German.

Risks

Open-House contracts can be terminated automatically if exclusive contracts are signed during the term, reducing value...

Stringent proof of drug authorization required; delays or missing documents may prevent participation.

Analysis may be incomplete

Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.

Key Requirements

Technical

  • Only authorized and marketable drugs in Germany may be supplied; proof via Lauer-Taxe listing or AMIce database extract.

Administrative

  • Submission of signed contract documents in paper form (not electronic) to the buyer.
  • First deadline for contracts starting 01.03.2025: documents must be received by 31.01.2025.

Requirements may be incomplete.

Buyer

Name

AOK Rheinland-Pfalz/Saarland - Die Gesundheitskasse

Location

Eisenberg, DEU

Buyer profile

Open profile

Identifier

DE271900642

Activity

Health

Lots (1)

LOT-0000

Abschluss nicht exklusiver Rabattverträge gemäß §§ 130a Abs. 8/130c Abs. 1 SGB V zu Arzneimitteln mit dem Wirkstoff Ritonavir (J05AE03) im Rahmen eines sogenannten Open-House-Modells.

Open-House discount agreements for Ritonavir (J05AE03) with non-exclusive contracts; all interested pharmaceutical companies can participate under uniform conditions. Contracts last up to 24 months (earliest start 01.03.2025, latest end 28.02.2027). Children's medicinal products per BfArM list are excluded.

SuppliesEU fundedElectronic submission

Location

DEB3D, Germany

Duration

Feb 2025 - Feb 2027

Category

Pharmaceutical products

Deadline

Deadline Dec 31, 2026

Procurement Details

Publication date
12 Jan 2025
Notice type
Contract notice — standard
Languages
German

Reference metadata

Notice subtype
16
Notice version
1
Legal basis
32014L0024

Reference IDs

Tender ID
20263-2025

Documents (1)

Similar tenders